NVO - ETFs Bet High On Weight Loss Drugs But Industry Observers Question Long-Term Potential | Benzinga
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged.
However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds (ETFs) need to evaluate their potential.
The Roundhill GLP-1 Weight Loss ETF (NASDAQ:OZEM) and the Amplify Weight Loss Drug and Treatment ETF (NYSE:THNR) debuted on May 21 with an expense ratio of 0.59%.
Both ETFs have significant weightings in industry giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), with OZEM and THNR allocating about 40% and 30%, respectively, to these companies.
Eli Lilly and ...